In a major advance in precision medicine, an international collaboration of researchers found 90 percent of castration resistant metastatic prostate cancers harbored some kind of genetic anomaly that could drive treatment choices.
Why do some cancer cells break away from a tumor and travel to distant parts of the body? A team of oncologists and engineers from the University of Michigan teamed up to help understand this crucial question.
A new urine-based test improved prostate cancer detection – including detecting more aggressive forms of prostate cancer – compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.
Researchers have developed and tested a new tool that searches for the most common genetic anomalies seen in cancer. The assay demonstrates the ability to make gene sequencing easier over a large volume of samples. In the future, this may mean that patients would not always need to undergo a fresh biopsy in order to identify a potential treatment strategy, as is currently necessary with more comprehensive sequencing approaches.
In certain types of cancer, nerves and cancer cells enter an often lethal and intricate waltz where cancer cells and nerves move toward one another and eventually engage in such a way that the cancer cells enter the nerves.
Lisa A. Newman, M.D., M.P.H., director of the Breast Care Center, is one of seven University of Michigan faculty members to receive the 2015 Harold R. Johnson Diversity Service Award from the Office of the Provost.
One of Ann Arbor’s most exciting educational events is back. One Day Closer gives individuals and families an up-close look at one of the world’s leading cancer research facilities and what its internationally-recognized scientists and colleagues are doing to discover the cure for cancer.